Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009;105:422-430
Published online before print July 23, 2009, doi: 10.1161/CIRCRESAHA.109.203323
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
105/5/422    most recent
CIRCRESAHA.109.203323v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tan, N. Y.
Right arrow Articles by Khachigian, L. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, N. Y.
Right arrow Articles by Khachigian, L. M.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Apoptosis
Right arrow Other Vascular biology
(Circulation Research. 2009;105:422.)
© 2009 American Heart Association, Inc.


Molecular Medicine

Angiotensin II–Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement

Nicole Y. Tan, Jian-Mei Li, Roland Stocker, Levon M. Khachigian

From the Centre for Vascular Research (N.Y.T., J.-M.L., L.M.K.), University of New South Wales, Sydney; and Centre for Vascular Research, University of Sydney (R.S.), Australia.

Correspondence to Levon M. Khachigian, PhD, DSc, Centre for Vascular Research, University of New South Wales, Sydney NSW 2052, Australia. E-mail L.Khachigian{at}unsw.edu.au

Rationale: Fas ligand (FasL)-mediated smooth muscle cell (SMC) apoptosis within the vulnerable plaque may lead to plaque instability and rupture, events that underlie myocardial infarction and stroke.

Objective: The molecular mechanisms underlying FasL transcription and FasL-dependent SMC apoptosis were investigated in this study in vitro and in vivo.

Methods and Results: We demonstrate that GATA-6, the predominant GATA family member expressed in SMCs, stimulates SMC apoptosis in an extracellular FasL-dependent manner. Both GATA-6 and FasL were inducibly and transiently expressed following balloon injury to rat carotid arteries. We identified two potential GATA binding in the FasL promoter and demonstrated using DNA binding and chromatin immunoprecipitation assays that GATA-6 regulates FasL through one (–298TTATCA–303) but not both these elements. Angiotensin II (Ang II) stimulated expression of both GATA-6 and FasL. Ang II increased SMC apoptosis in an Ang II type 2 receptor–, caspase 8–, and FasL-dependent fashion. GATA-6 activation was MEK-ERK1/2– and JNK-dependent, and GATA-6 small interfering RNA blocked Ang II–inducible FasL expression and SMC apoptosis. Administration of Ang II to rats increased FasL expression and apoptosis in carotid artery SMCs in an Ang II type 2 receptor– and GATA-6–dependent manner.

Conclusions: This study provides new insights into the transcriptional events underpinning FasL-dependent SMC apoptosis after exposure to Ang II.


Key Words: Fas ligand • GATA-6 • apoptosis • angiotensin II